Selected research
Industry Research
Metastatic Prostate Industry Research Report 2026
Market perspective
The global Metastatic Prostate market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Metastatic Prostate market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Metastatic Prostate market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Metastatic Prostate market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Metastatic Prostate include Genentech, BeiGene, Amgen, Zenith Epigenetics Ltd., VasGene Therapeutics, Inc., Telix Pharmaceuticals, SeleXel, Myovant Biosciences and Immunomedics(Gilead Sciences, Inc.), among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Metastatic Prostate market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Metastatic Prostate.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Metastatic Prostate Market by Company
Genentech
BeiGene
Amgen
Zenith Epigenetics Ltd.
VasGene Therapeutics, Inc.
Telix Pharmaceuticals
SeleXel
Myovant Biosciences
Immunomedics(Gilead Sciences, Inc.)
eFFECTOR Therapeutics
Arvinas Inc.
AB Science
Metastatic Prostate Segment by Type
Mono
Mono/Combination
Combination
Metastatic Prostate Segment by Application
Hospital
Drug Store
Online Pharmacy
Metastatic Prostate Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metastatic Prostate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Metastatic Prostate and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metastatic Prostate.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Metastatic Prostate companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Mono
- Mono/Combination
- Combination
Applications
- Hospital
- Drug Store
- Online Pharmacy
Companies covered
- Genentech
- BeiGene
- Amgen
- Zenith Epigenetics Ltd.
- VasGene Therapeutics, Inc.
- Telix Pharmaceuticals
- SeleXel
- Myovant Biosciences
- Immunomedics(Gilead Sciences, Inc.)
- eFFECTOR Therapeutics
- Arvinas Inc.
- AB Science
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Metastatic Prostate by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Mono
- 2.2.3 Mono/Combination
- 2.2.4 Combination
- 2.3 Metastatic Prostate by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Drug Store
- 2.3.4 Online Pharmacy
- 2.4 Assumptions and Limitations
3 Metastatic Prostate Breakdown Data by Type
- 3.1 Global Metastatic Prostate Historic Market Size by Type (2021-2026)
- 3.2 Global Metastatic Prostate Forecasted Market Size by Type (2027-2032)
4 Metastatic Prostate Breakdown Data by Application
- 4.1 Global Metastatic Prostate Historic Market Size by Application (2021-2026)
- 4.2 Global Metastatic Prostate Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Metastatic Prostate Market Perspective (2021-2032)
- 5.2 Global Metastatic Prostate Growth Trends by Region
- 5.2.1 Global Metastatic Prostate Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Metastatic Prostate Historic Market Size by Region (2021-2026)
- 5.2.3 Metastatic Prostate Forecasted Market Size by Region (2027-2032)
- 5.3 Metastatic Prostate Market Dynamics
- 5.3.1 Metastatic Prostate Industry Trends
- 5.3.2 Metastatic Prostate Market Drivers
- 5.3.3 Metastatic Prostate Market Challenges
- 5.3.4 Metastatic Prostate Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Metastatic Prostate Players by Revenue
- 6.1.1 Global Top Metastatic Prostate Players by Revenue (2021-2026)
- 6.1.2 Global Metastatic Prostate Revenue Market Share by Players (2021-2026)
- 6.2 Global Metastatic Prostate Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Metastatic Prostate Head Office and Area Served
- 6.4 Global Metastatic Prostate Players, Product Type & Application
- 6.5 Global Metastatic Prostate Manufacturers Established Date
- 6.6 Global Metastatic Prostate Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Metastatic Prostate Market Size (2021-2032)
- 7.2 North America Metastatic Prostate Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Metastatic Prostate Market Size by Country (2021-2026)
- 7.4 North America Metastatic Prostate Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Metastatic Prostate Market Size (2021-2032)
- 8.2 Europe Metastatic Prostate Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Metastatic Prostate Market Size by Country (2021-2026)
- 8.4 Europe Metastatic Prostate Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Metastatic Prostate Market Size (2021-2032)
- 9.2 Asia-Pacific Metastatic Prostate Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Metastatic Prostate Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Metastatic Prostate Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Metastatic Prostate Market Size (2021-2032)
- 10.2 South America Metastatic Prostate Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Metastatic Prostate Market Size by Country (2021-2026)
- 10.4 South America Metastatic Prostate Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Metastatic Prostate Market Size (2021-2032)
- 11.2 Middle East & Africa Metastatic Prostate Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Metastatic Prostate Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Metastatic Prostate Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Genentech
- 12.1.1 Genentech Company Information
- 12.1.2 Genentech Business Overview
- 12.1.3 Genentech Revenue in Metastatic Prostate Business (2021-2026)
- 12.1.4 Genentech Metastatic Prostate Product Portfolio
- 12.1.5 Genentech Recent Developments
- 12.2 BeiGene
- 12.2.1 BeiGene Company Information
- 12.2.2 BeiGene Business Overview
- 12.2.3 BeiGene Revenue in Metastatic Prostate Business (2021-2026)
- 12.2.4 BeiGene Metastatic Prostate Product Portfolio
- 12.2.5 BeiGene Recent Developments
- 12.3 Amgen
- 12.3.1 Amgen Company Information
- 12.3.2 Amgen Business Overview
- 12.3.3 Amgen Revenue in Metastatic Prostate Business (2021-2026)
- 12.3.4 Amgen Metastatic Prostate Product Portfolio
- 12.3.5 Amgen Recent Developments
- 12.4 Zenith Epigenetics Ltd.
- 12.4.1 Zenith Epigenetics Ltd. Company Information
- 12.4.2 Zenith Epigenetics Ltd. Business Overview
- 12.4.3 Zenith Epigenetics Ltd. Revenue in Metastatic Prostate Business (2021-2026)
- 12.4.4 Zenith Epigenetics Ltd. Metastatic Prostate Product Portfolio
- 12.4.5 Zenith Epigenetics Ltd. Recent Developments
- 12.5 VasGene Therapeutics, Inc.
- 12.5.1 VasGene Therapeutics, Inc. Company Information
- 12.5.2 VasGene Therapeutics, Inc. Business Overview
- 12.5.3 VasGene Therapeutics, Inc. Revenue in Metastatic Prostate Business (2021-2026)
- 12.5.4 VasGene Therapeutics, Inc. Metastatic Prostate Product Portfolio
- 12.5.5 VasGene Therapeutics, Inc. Recent Developments
- 12.6 Telix Pharmaceuticals
- 12.6.1 Telix Pharmaceuticals Company Information
- 12.6.2 Telix Pharmaceuticals Business Overview
- 12.6.3 Telix Pharmaceuticals Revenue in Metastatic Prostate Business (2021-2026)
- 12.6.4 Telix Pharmaceuticals Metastatic Prostate Product Portfolio
- 12.6.5 Telix Pharmaceuticals Recent Developments
- 12.7 SeleXel
- 12.7.1 SeleXel Company Information
- 12.7.2 SeleXel Business Overview
- 12.7.3 SeleXel Revenue in Metastatic Prostate Business (2021-2026)
- 12.7.4 SeleXel Metastatic Prostate Product Portfolio
- 12.7.5 SeleXel Recent Developments
- 12.8 Myovant Biosciences
- 12.8.1 Myovant Biosciences Company Information
- 12.8.2 Myovant Biosciences Business Overview
- 12.8.3 Myovant Biosciences Revenue in Metastatic Prostate Business (2021-2026)
- 12.8.4 Myovant Biosciences Metastatic Prostate Product Portfolio
- 12.8.5 Myovant Biosciences Recent Developments
- 12.9 Immunomedics(Gilead Sciences, Inc.)
- 12.9.1 Immunomedics(Gilead Sciences, Inc.) Company Information
- 12.9.2 Immunomedics(Gilead Sciences, Inc.) Business Overview
- 12.9.3 Immunomedics(Gilead Sciences, Inc.) Revenue in Metastatic Prostate Business (2021-2026)
- 12.9.4 Immunomedics(Gilead Sciences, Inc.) Metastatic Prostate Product Portfolio
- 12.9.5 Immunomedics(Gilead Sciences, Inc.) Recent Developments
- 12.10 eFFECTOR Therapeutics
- 12.10.1 eFFECTOR Therapeutics Company Information
- 12.10.2 eFFECTOR Therapeutics Business Overview
- 12.10.3 eFFECTOR Therapeutics Revenue in Metastatic Prostate Business (2021-2026)
- 12.10.4 eFFECTOR Therapeutics Metastatic Prostate Product Portfolio
- 12.10.5 eFFECTOR Therapeutics Recent Developments
- 12.11 Arvinas Inc.
- 12.11.1 Arvinas Inc. Company Information
- 12.11.2 Arvinas Inc. Business Overview
- 12.11.3 Arvinas Inc. Revenue in Metastatic Prostate Business (2021-2026)
- 12.11.4 Arvinas Inc. Metastatic Prostate Product Portfolio
- 12.11.5 Arvinas Inc. Recent Developments
- 12.12 AB Science
- 12.12.1 AB Science Company Information
- 12.12.2 AB Science Business Overview
- 12.12.3 AB Science Revenue in Metastatic Prostate Business (2021-2026)
- 12.12.4 AB Science Metastatic Prostate Product Portfolio
- 12.12.5 AB Science Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst